Vmbook Online ordering
Biotechnology
Sure, here is some general information about Apollon Formularies Inc. (APDN)
* Apollon Formularies Inc. operates as a clinical-stage biopharmaceising as a holding company corporation that designs, develops, and commercialises botanical- based cannabinoid therapeutics and CBD products.
* Apollon Formularies, Inc. operates in the biotechnology industry and is listed on the OTCQB market under the ticker symbol APDN.
* The company's pipeline includes therapies for COVID-19, cancer, and respiratory disorders.
* Its lead candidate is APDN-1111, a proprietary nanoTHC formulation for treating COVID-19 patients with low oxygen levels.
* Apollon Formularies' product pipeline also includes APDN-110, a proprietary nano-CBD formulation for the treatment of cancer and respiratory diseases.
* Apollon Formularies, Inc., a biotechnology company, focuses on developing and commercialising therapeutic products derived from botanicals, such as cannabinoids, terpenes, and flavonoids.
* Apollon Formularies, Inc., was founded in 2019 and has its headquarters at 4740 Irving Blvd, Dallas, Texas 75390, United States.
In terms of financials, Apollon Formularies, Inc reported earnings of - $0.01 per share in its most recent quarterly earnings report on February 14, 2023. (Q3). The business earned 281.69 thousand dollars in revenue during the quarter. These earnings came to $0.01 per share.
In terms of growth, the company has stated that it is focused on advancing its product pipeline and expanding its global footprint through strategic partnerships and collaborations, which could potentially drive future growth.
Based on the current data, not enough data is available to predict future earnings, revenue, or growth with certainty. However, the company's pipeline and expansion strategy indicate promise, offering potential for future development. It is, however, essential to look at the biotech sector's volatility and regulatory factors impacting cannabinoid-based therapeutics. Before making any investment decisions, conducting extensive research and analysing future corporate reports are crucial.
I hope this information has been helpful. Do you need any more assistance?